Venus MedTech (HangZhou) Inc.
Room 201, Shuiyou Building,
No.3738, Nanhuan Road, Binjiang District
About Venus MedTech (HangZhou) Inc.Venus MedTech (HangZhou) Inc. is located in Hangzhou National High-tech Industrial Development Zone (Binjiang), with its products positioned in the development and industrialization of international advanced interventional artificial cardiac valve system, filling up the blank in China.
Interventional artificial aortic valve products researched and developed by the company takes the lead in finishing clinical tests in China. In reference to the development and promotion conditions of coronary stents at home and abroad, interventional artificial cardiac valve, as a revolutionary treatment means, has been increasingly recognized by experts, and will take on an explosible increase of clinical needs in the foreseeable next few years.
15 articles with Venus MedTech (HangZhou) Inc.
Venus Medtech Appoints Professor Martin B. Leon as Global Principal Investigator of Its New-Generation RDN System
On July 27, 2021, Venus Medtech Inc., a leading provider of comprehensive interventional heart valve therapy solutions in China, and its controlling subsidiary Renaly Ltd., announced that Professor Martin B. Leon, MD, a pioneer in the field of interventional cardiovascular devices, has been appointed as the Global Principal Investigator for its new-generation renal artery denervation system.
Venus Medtech Inc., the leading transcatheter heart valve medical device player in China, and Pi-Cardia Ltd., a global leader in the development of non-implant catheter-based solutions for treating heart valve calcification, announced a collaboration to bring Pi-Cardia's Leaflex™ technology to China.
Venus Medtech and Opus Medical Therapies, LLC Announce Partnership for Transcatheter Mitral Valve Replacement (TMVR) and Transcatheter Tricuspid Valve Replacement (TTVR) in Greater China Market
Venus Medtech Inc., the leading Chinese transcatheter heart valve company and Opus Medical Therapies, LLC, a medical device company focused on developing transcatheter mitral and tricuspid valve replacement products for patients undergoing mitral and tricuspid valve disease, announced a partnership agreement to develop, manufacture and sell these TMVR and TTVR products in Greater China.
The leading transcatheter heart valve medical device player in China - Venus Medtech Inc., is pleased to announce the appointment of two new cardiovascular experts to its advisory team.
Venus Medtech has retained four world-renowned experts specialized in interventional cardiovascular to form a Global Advisory Board.
First Clinical Implantation of Transcatheter Pulmonary Valve VenusP-Valve in North America was Successfully Performed in Vancouver, Canada
Venus Medtech Release: First Successful Clinical Implantation of Transcatheter Pulmonary Valve VenusP-Valve was Successfully Completed in Brazil
On December 19, 2017, local time, 4 clinical implantations of transcatheter pulmonary valve VenusP-Valve were successfully completed in Brazil by Professor Carlos Pedra from Dante Pazzanese Institute of Cardiovascular Technology in Sao Paulo, Brazil.
Venus Medtech Release: China Successfully Completes the Country's First Human Implantation of a Retrievable Transcatheter Aortic Valve
- The success of the procedure unleashes a new era for retrievable interventional cardiac valve technology in China [28-November-2017] HANGZHOU, China, Nov. 28, 2017 /PRNewswire/ -- The first human implantation of the VenusA Plus retrievable valve system was completed successfully at the Second Affiliated Hospital of Zhejiang University School of Medicine (SA
Venus MedTech Acquires U.S. Company InterValve To Create A Systematic TAVR Treatment And Strengthen Global Expansion
Venus MedTech's TAVR Device Is Approved By CFDA, Creating A New Era Of Interventional Cardiology In China
Keystone Heart And Venus MedTech Announce Partnership For Cerebral Embolic Protection With Transcatheter Heart Valve Systems (TAVR) In China And Key Asian Markets
The Successful Worldwide First In Human Implantation Of An Innovative Aortic Valve From Colibri Heart Valve, LLC And Venus MedTech With Disruptive "Dry Tissue" Technology Conducted
Venus MedTech's Transcatheter Pulmonary Valve Debuts In Europe, Marking The Start Of Global Clinical Trial